Expert Details Latest Data Across GI Cancers

Newsfeed Image, Light Gray Text On Dark Gray Background
Among the gastrointestinal (GI) cancer findings presented at the 2018 ASCO Annual Meeting, the phase III PRODIGE 24/CCTG PA.6 trial results were the most significant, said Susanna Ulahannan, MD.

In PRODIGE 24, adjuvant therapy with a modified FOLFIRINOX regimen (mFOLFIRINOX) drastically improved survival compared with gemcitabine for patients with resected pancreatic cancer.                Read more . . .